Advances in nano crystal science for targeted cancer therapy: a state-of-the-art review

Poonam Yadav*[1], Devendra Kaushik[2], Rohit[3], Dawan Kumar [4], Kapil Kumar [5]

*[*1]Department of Pharmacology, School of Healthcare & Allied Sciences, GD Goenka University, Sohna-Gurgaon Road, Sohna, 122103, Haryana, India.*

[2,5]Department of Pharmaceutics, School of Healthcare & Allied Sciences, GD Goenka University, Sohna-Gurgaon Road, Sohna, 122103, Haryana, India.

[3]Department of Pharmaceutics, Rao Neki Ram Memorial college of Pharmacy, Turkapur road, Turkapur Teh. Pataudi Distt. Gurgaon Haryana-122503, India.

[4]Department of Pharmacognosy, School of Healthcare & Allied Sciences, GD Goenka University, Sohna-Gurgaon Road, Sohna, 122103, Haryana, India.

***Corresponding author: Poonam Yadav,**

Department of Pharmacology, School of Healthcare & Allied Sciences, GD Goenka University, Sohna-Gurgaon Road, Sohna, 122103, Haryana, India. E-mail: poonamyadav98958@gmail.com

Abstract

Nano crystal science has emerged as a forefront area of research with profound implications for targeted cancer therapy. This state-of-the-art review provides a comprehensive overview of the latest advances in nano crystal technologies, focusing on their applications in the field of cancer treatment. The paper encompasses a broad spectrum of topics, including design principles, fabrication methods, and therapeutic strategies employed in the development of nano crystals for precise and effective cancer therapy. The review the fundamental principles of nano crystals and their unique properties that make them promising candidates for targeted drug delivery. Special attention is given to the advancements in fabrication techniques, ranging from traditional bottom-up approaches to cutting-edge top-down methods, allowing for the precise control of size, shape, and surface properties of nano crystals. A significant portion of the paper is dedicated to the innovative strategies employed in functionalizing nano crystals for targeted cancer therapy. This includes the incorporation of specific ligands, antibodies, or peptides onto the surface of nano crystals to enhance their affinity and selectivity toward cancer cells. The review also explores the integration of imaging modalities for real-time monitoring of drug delivery and therapeutic response. The state-of-the-art survey delves into the evolving landscape of nano crystal-based drug formulations, discussing the encapsulation and controlled release of anticancer agents.

Moreover, the paper highlights recent breakthroughs in the design of stimuli-responsive nano crystals that enable on-demand drug release, maximizing therapeutic efficacy while minimizing off-target effects. In addition to exploring the role of nano crystals in drug delivery, the review examines their potential in other facets of cancer therapy, such as photothermal and photodynamic therapy. The synergistic combination of nano crystals with various therapeutic modalities demonstrates the versatility of these nanomaterials in addressing the multifaceted challenges of cancer treatment. The review critically assesses the current challenges and limitations in the field, addressing issues related to biocompatibility, scalability, and long-term safety. Furthermore, it discusses regulatory considerations and the translation of nano crystal-based therapies from bench to bedside, emphasizing the importance of bridging the gap between preclinical research and clinical applications. By illuminating the latest breakthroughs, challenges, and future directions, this review aims to guide researchers, clinicians, and policymakers in harnessing the full potential of nano crystals for advancing precision cancer therapy.

***Keywords**: Nano crystal, nanomaterials, policymakers, anticancer agents, preclinical research, targeted drug delivery, targeted cancer therapy.*

1. Introduction

In the realm of cancer therapy, the intersection of nanotechnology and crystal science has emerged as a pioneering domain with the potential to revolutionize treatment strategies [1]. Nano crystals, characterized by their unique size and structure, present a promising avenue for targeted drug delivery and enhanced therapeutic outcomes. This state-of-the-art review aims to provide a comprehensive overview of recent advances in nano crystal science, focusing on its applications in the precision targeting of cancer cells [2,3]. Conventional cancer therapy faces hurdles like systemic toxicity, restricted bioavailability, and off-target effects with traditional chemotherapy, underscoring the need for innovative solutions in precision medicine. Nano crystals, characterized by unique physicochemical properties, herald a paradigm shift in medicine, providing a versatile platform for designing targeted drug delivery systems [4]. Their tailored properties enable precise control over drug release, enhancing therapeutic efficacy while minimizing adverse effects, marking a transformative advancement in pharmaceutical science. Nano crystals, defined by their nanoscale dimensions, exhibit size-dependent properties and distinctive surface characteristics [5,6]. At this scale, quantum effects become pronounced, influencing optical, electronic, and catalytic behaviors. This characterization underscores their potential in diverse applications, from advanced materials to targeted drug delivery systems, defining a burgeoning field of research. The exploration of nano crystals encompasses various types, each with unique attributes. Metallic nano crystals exhibit exceptional conductivity, polymeric ones offer versatile structural properties, and lipid-based formulations provide biocompatible carriers. Understanding these diverse categories is crucial for tailoring nano crystals to specific applications, fostering innovation in fields such as medicine and materials science [7].



Fig.1 A schematic illustration of the various types of Nano-crystals

2. Methods of nanocrystals

The fabrication of nanocrystals incorporates cutting-edge techniques that seamlessly blend both bottom-up and top-down approaches, harnessing the advantages of each methodology. Bottom-up techniques, epitomized by methods such as chemical precipitation, sol-gel synthesis, and hydrothermal processes, empower the assembly of nanocrystals atom by atom [8,9]. This meticulous construction allows for unparalleled control over size, shape, and composition, enabling the tailoring of nanomaterials with precise specifications. Conversely, top-down methods, including mechanical milling, laser ablation, and various template-assisted approaches, involve the transformation of larger materials into nanoscale entities [10]. This approach ensures scalability and efficiency in the fabrication process, addressing the practical demands of large-scale production for industrial applications. This amalgamation of bottom-up and top-down strategies forms a comprehensive toolkit for nanocrystal fabrication, highlighting the versatility and precision achievable in the creation of nanomaterials [11,12]. Researchers and engineers can leverage these advanced methods to craft nanocrystals with tailored properties suited for diverse applications, spanning fields such as electronics, medicine, catalysis, and materials science. The integration of these state-of-the-art techniques underscores the dynamic nature of nanotechnology and its pivotal role in advancing scientific and technological frontiers [13].

Precision engineering has propelled notable advances in tailoring nano crystal properties with unprecedented accuracy. Techniques like molecular self-assembly enable meticulous control over structure and morphology. Surface modification strategies, such as ligand functionalization, afford precise tuning of chemical characteristics [14]. These innovations empower researchers to fine-tune parameters like size, shape, and surface charge, optimizing nano crystals for targeted applications in fields ranging from medicine to electronics. This discussion highlights the transformative impact of precision engineering in advancing the capabilities of nano crystals [15,16].

3. Targeted Drug Delivery

Innovative approaches to functionalize nano crystals for targeted drug delivery are examined, emphasizing surface modifications. This involves the strategic incorporation of ligands, antibodies, and peptides onto nano crystal surfaces. Ligands enhance specificity by targeting specific receptors, antibodies enable immune system recognition, and peptides facilitate cell penetration [17].

This sophisticated functionalization enables tailored interactions, ensuring precise drug delivery to targeted cells. Such advancements underscore the pivotal role of nano crystals in the evolution of personalized medicine and targeted therapies with enhanced therapeutic efficacy and reduced off-target effects [18]. The integration of imaging modalities represents a pivotal advancement in nano crystal research, enabling real-time monitoring of drug delivery and therapeutic response. By incorporating imaging agents into nano crystal formulations, researchers gain insights into their distribution and interaction with target tissues. Techniques like fluorescence imaging, magnetic resonance imaging (MRI), and positron emission tomography (PET) offer non-invasive means to track drug kinetics, fostering a deeper understanding of therapeutic outcomes and facilitating the refinement of nano crystal-based drug delivery systems for improved precision and efficacy [19,20].

The in-depth analysis of encapsulation and controlled release mechanisms within nano crystals reveals a dynamic landscape at the forefront of cancer therapeutics. Nano crystals serve as versatile carriers for encapsulating anticancer agents, safeguarding them during transport and enhancing their stability [21]. This encapsulation not only shields the agents from degradation but also facilitates their targeted delivery to cancer cells. Controlled release mechanisms embedded in nano crystals allow for precise modulation of drug release kinetics. Factors such as environmental triggers (pH, temperature), enzymatic activity, or external stimuli can be harnessed to dictate the pace of drug release. This level of control is crucial for optimizing therapeutic efficacy, ensuring sustained drug concentrations within the target site while minimizing systemic exposure and associated side effects [22].

4. Advantages of nanocrystals

The advantages of nano crystal-based controlled release extend beyond temporal regulation; they also enable spatial precision. By tailoring the properties of nano crystals, researchers can achieve site-specific drug delivery, guiding therapeutic payloads to the tumor microenvironment. This spatial precision minimizes damage to healthy tissues and enhances the therapeutic index of anticancer agents. Moreover, nano crystals with stimuli-responsive capabilities respond dynamically to the unique conditions of the tumor environment [23]. pH-responsive nano crystals, for example, release drugs selectively in the acidic tumor microenvironment, further enhancing targeted treatment. In conclusion, the in-depth analysis of encapsulation and controlled release within nano crystals showcases their potential as sophisticated drug delivery vehicles in cancer therapy [24]. This research avenue promises not only enhanced therapeutic outcomes but also a paradigm shift towards more precise and personalized approaches in the fight against cancer The exploration of stimuli-responsive nano crystals represents a cutting-edge frontier in drug delivery, offering unprecedented control over drug release for enhanced therapeutic precision. These nano crystals are designed to respond selectively to specific stimuli present in the microenvironment, allowing for on-demand and site-specific drug release. One key aspect of stimuli-responsive nano crystals is their responsiveness to variations in pH levels [25]. In the context of cancer therapy, the slightly acidic pH of the tumor microenvironment can trigger the release of encapsulated drugs.

This pH-sensitive behavior ensures that drug delivery is predominantly activated within the tumor, minimizing systemic exposure and associated side effects. Temperature-responsive nano crystals exhibit a similar principle, releasing drugs in response to temperature changes characteristic of the target tissue [26]. Such precision in drug release enables tailored therapeutic strategies, particularly useful in hyperthermia-based cancer treatments where localized heating triggers drug release for synergistic therapeutic effects. Beyond pH and temperature, stimuli-responsive nano crystals can exploit enzymatic activity or light exposure to achieve controlled drug release. Enzyme-triggered release is particularly relevant in pathological conditions where specific enzymes are over expressed, providing a mechanism for targeted drug delivery. This exploration of stimuli-responsive nano crystals not only showcases their versatility but also underscores their potential to revolutionize drug delivery strategies [27]. By providing an on-demand release of therapeutic agents precisely where and when needed, these nano crystals hold immense promise for advancing the field of personalized medicine and optimizing treatment outcomes while minimizing adverse effects. Nano crystals play a pivotal role in advancing therapeutic modalities, notably in photothermal and photodynamic therapy, offering multifaceted approaches to cancer treatment [28]. In photothermal therapy, nano crystals with unique optical properties absorb light energy, converting it into heat and selectively ablating cancer cells. This targeted hyperthermia induces localized cell damage, making it an attractive strategy for precise tumor treatment while minimizing damage to surrounding healthy tissues. Conversely, in photodynamic therapy, nano crystals serve as carriers for photosensitizing agents. Upon exposure to specific wavelengths of light, these agents generate reactive oxygen species, inducing cell death in targeted cancer cells [29]. Nano crystals facilitate the controlled delivery of photosensitizers, enhancing the specificity and efficiency of photodynamic therapy. Beyond cancer treatment, nano crystals are finding applications in other therapeutic modalities. They can be engineered to carry therapeutic payloads, including genes or proteins, facilitating targeted delivery to specific cells. Additionally, their unique physicochemical properties make them promising candidates for drug delivery systems in various diseases, showcasing their versatility in diverse therapeutic applications [30].

Table 1. Applications and Advantages of Nanocrystals in Medical Therapy

Aspect	Key Features and Applications
Controlled Release	Enables temporal and spatial precision in drug delivery
Stimuli-Responsive Capabilities	pH-responsive release in acidic tumor environment
Therapeutic Applications	Photothermal therapy (heat-based cancer treatment)
Advantages in Cancer Treatment	Enhanced therapeutic precision
Current Challenges	Biocompatibility concerns
Future Trends	AI/ML integration in design

The role of nano crystals in these therapeutic modalities reflects a paradigm shift toward precision medicine, where treatment strategies can be tailored to individual patients. As research progresses, the integration of nano crystals in therapeutic approaches holds the potential to redefine the landscape of medical interventions, offering more effective and targeted treatments with reduced side effects [31]. The synergistic integration of nano crystals with traditional treatment approaches represents a groundbreaking strategy that holds immense promise in enhancing therapeutic outcomes across various medical disciplines. When combined with conventional therapies such as chemotherapy or radiotherapy, nano crystals bring about a synergistic effect, addressing the limitations of each approach while maximizing efficacy. In chemotherapy, nano crystals can serve as drug carriers, enhancing the pharmacokinetics and bioavailability of chemotherapeutic agents. Their ability to encapsulate and deliver drugs precisely to target sites mitigates systemic toxicity and reduces off-target effects [32]. This targeted drug delivery, when combined with conventional chemotherapy, enhances the overall therapeutic impact. Similarly, in radiotherapy, nano crystals can be employed to sensitize tumor cells to radiation. Their unique properties, such as high surface area and the potential for surface modification, allow for the enhancement of radio sensitization effects, leading to increased radiation-induced cell damage within the tumor while sparing surrounding healthy tissues. The combination of nano crystals with immunotherapy, another emerging field in cancer treatment, showcases their potential to modulate the immune response. Nano crystals can be engineered to carry immunomodulatory agents, enhancing the activation of the immune system against cancer cells and amplifying the effects of immunotherapeutic interventions [33]. This illustration of synergistic potential underscores the transformative impact of integrating nano crystals with traditional treatments. The synergy not only addresses the limitations of individual therapies but also opens new avenues for developing comprehensive and personalized treatment strategies, marking a paradigm shift in the landscape of medical interventions. A critical assessment of current challenges in nano crystal research reveals several crucial issues that must be addressed to ensure the successful translation of these promising technologies from the laboratory to practical clinical applications. Biocompatibility stands out as a paramount concern, as the introduction of nano crystals into the human body demands rigorous evaluation of potential adverse effects. Understanding how nano crystals interact with biological systems and ensuring their compatibility with the complex physiological environment is essential to avoid unintended toxicity and immune responses [34]. Scalability poses another significant challenge. While many nano crystal fabrication methods exhibit success at the laboratory scale, translating these processes to industrial levels for mass production remains a hurdle. Achieving reproducibility, maintaining quality control, and optimizing cost-effectiveness are critical factors for the widespread adoption of nano crystal-based therapies. Long-term safety considerations are paramount in assessing the viability of nano crystal applications. Limited knowledge exists about the potential accumulation of nano crystals in organs and tissues over extended periods. Research must focus on elucidating the biodegradability and clearance mechanisms of these materials to address concerns related to their persistence and long-term impact on human health [35].

Furthermore, regulatory frameworks need refinement to accommodate the unique characteristics of nano crystals. Standardization of testing protocols and establishment of safety guidelines are imperative to streamline the regulatory approval process and ensure the responsible development of nano crystal-based therapeutics. In conclusion, a critical assessment of challenges, encompassing biocompatibility, scalability, and long-term safety, underscores the need for comprehensive research efforts. Addressing these challenges is essential for realizing the full potential of nano crystals in medical applications, fostering innovation, and ensuring their safe and effective integration into clinical practice [36]. The journey from preclinical studies to clinical applications for nano crystal-based therapies involves navigating a complex landscape of regulatory considerations and translational hurdles. Regulatory bodies worldwide play a crucial role in ensuring the safety and efficacy of novel medical interventions, and nano crystals, being a relatively nascent technology, present unique challenges in terms of classification, evaluation, and approval [37]. One significant regulatory consideration is the need for standardized testing protocols that align with the distinctive properties of nano crystals. Traditional assessment methods may fall short in capturing the nuanced interactions of nano crystals within biological systems. Regulatory agencies must collaborate with researchers to develop robust testing standards that account for the specific characteristics of nano crystals, ensuring comprehensive safety and efficacy evaluations. The classification of nano crystals poses challenges as well. Determining their regulatory status—whether as a drug, medical device, or combination product—can influence the regulatory pathway they follow. Each category comes with its own set of requirements, making it imperative to establish clear guidelines that consider the diverse nature of nano crystals and their intended applications. Translational hurdles arise from the gap between preclinical efficacy studies and the practical challenges encountered in clinical settings. While preclinical studies may demonstrate the therapeutic potential of nano crystals, their real-world application involves variables such as patient variability, complex biological responses, and unforeseen interactions. Bridging this gap requires extensive collaboration between researchers, clinicians, and regulatory agencies to address uncertainties and refine protocols for clinical trials [38].

Moreover, the long and expensive process of clinical development necessitates strategic planning and substantial financial investment. Securing funding for clinical trials, especially for novel technologies like nano crystals, requires engagement with private investors, pharmaceutical companies, or government funding agencies. The risk associated with these investments, coupled with uncertainties in the regulatory approval process, poses a substantial translational hurdle. Ethical considerations also play a pivotal role in the translational journey. Ensuring informed consent, safeguarding patient rights, and addressing potential societal concerns about the use of nanotechnology in medicine are essential aspects that demand careful attention [39]. In conclusion, the examination of regulatory considerations and translational hurdles underscores the intricate path from preclinical studies to clinical applications for nano crystal-based therapies. A harmonized approach involving collaboration between researchers, regulatory bodies, and stakeholders is essential to streamline regulatory processes, address translational challenges, and responsibly advance the integration of nano crystals into clinical practice.

This multidisciplinary effort is crucial for realizing the full potential of nano crystals in revolutionizing medical interventions and improving patient outcomes. The exploration of emerging trends and future directions in nano crystal research for targeted cancer therapy unveils a dynamic landscape poised for transformative advancements. One notable trend is the integration of artificial intelligence (AI) and machine learning (ML) in nano crystal design and optimization. Harnessing these technologies allows for rapid screening of vast material databases, accelerating the identification of novel nano crystals with optimal properties for targeted drug delivery. Another promising avenue is the development of theranostic nano crystals, combining therapeutic and diagnostic functionalities in a single platform. These multifunctional nano crystals enable simultaneous drug delivery and real-time monitoring of treatment response, providing clinicians with valuable insights into treatment efficacy and allowing for adaptive therapy strategies. Innovations in surface engineering represent a key trend, with researchers exploring advanced coating techniques to enhance the biocompatibility and targeting capabilities of nano crystals. Surface modifications with biomimetic materials or smart polymers enable improved evasion of the immune system, prolonged circulation in the bloodstream, and enhanced specific targeting to cancer cells [40].

5. Factors affecting nanocrystals

The incorporation of stimuli-responsive elements into nano crystals is a future direction that holds great potential. By designing nano crystals that respond to specific cues within the tumor microenvironment, such as pH, temperature, or enzymatic activity, researchers aim to achieve precise control over drug release, further optimizing therapeutic outcomes while minimizing off-target effects. Nanoparticle-based combination therapies are gaining prominence as researchers recognize the advantages of synergistic treatment approaches. The simultaneous delivery of multiple therapeutic agents using nano crystals offers a comprehensive strategy to combat the complexity of cancer heterogeneity and reduce the risk of resistance development. Additionally, personalized nano medicine is emerging as a future direction, wherein nano crystals are tailored to individual patient profiles. Utilizing patient-specific genetic and molecular information, researchers can design nano crystals that address the unique characteristics of a patient's tumor, paving the way for truly personalized and targeted cancer treatments. As nano crystal research continues to evolve, interdisciplinary collaboration, data sharing, and a focus on clinical translation will be imperative. These emerging trends and future directions collectively promise to redefine the landscape of targeted cancer therapy, offering innovative solutions that enhance treatment efficacy, minimize side effects, and move toward a more patient-centric approach in oncology. The consideration of nano crystals in the broader context of personalized medicine holds profound implications for the future of clinical practice, heralding a paradigm shift towards tailored interventions that prioritize individual patient needs and characteristics [41]. One of the primary contributions of nano crystals to personalized medicine lies in their ability to facilitate targeted drug delivery. By tailoring nano crystals to encapsulate therapeutic agents specific to the molecular profile of a patient's cancer, treatment becomes highly individualized.

This precision medicine approach minimizes the exposure of healthy tissues to potent therapies, reducing side effects and improving overall treatment tolerability. Furthermore, the design of nano crystals can be customized based on a patient's unique genetic and molecular markers. The integration of patient-specific data allows researchers to create nano crystals with enhanced specificity, optimizing their ability to target cancer cells while sparing healthy tissues. This level of customization not only increases the efficacy of cancer treatments but also opens avenues for addressing issues of treatment resistance and heterogeneity within tumors. The potential impact on clinical practice is far-reaching. Nano crystals, when integrated into routine medical protocols, may enable clinicians to make more informed decisions regarding treatment strategies. Imaging modalities incorporated into nano crystals provide real-time monitoring of drug delivery and treatment response, allowing for adaptive therapeutic interventions. Clinicians can adjust treatment plans based on dynamic patient responses, optimizing outcomes and minimizing the risk of adverse effects. The reduction of systemic toxicity is a crucial implication for clinical practice. Traditional cancer treatments often result in collateral damage to healthy tissues, leading to debilitating side effects. Nano crystals, with their targeted drug delivery capabilities, offer the prospect of minimizing these systemic effects. This not only improves the quality of life for cancer patients but also expands treatment options for individuals who may be ineligible for standard therapies due to comorbidities or frail health [42].

Moreover, nano crystals contribute to overcoming challenges associated with drug resistance. Through the simultaneous delivery of multiple therapeutic agents or the use of stimuli-responsive features, nano crystals can circumvent resistance mechanisms that commonly emerge during cancer treatment [43]. This is particularly significant in cases where conventional therapies may lose efficacy over time. The advent of personalized nano medicine necessitates advancements in diagnostics and molecular profiling. Integrated diagnostic tools can provide comprehensive information about a patient's cancer, guiding the design of nano crystals for optimal therapeutic impact. This convergence of diagnostics and therapeutics marks a paradigmatic shift from reactive to proactive healthcare, aligning with the principles of personalized medicine. In conclusion, the consideration of nano crystals in the realm of personalized medicine heralds a transformative era in clinical practice. The potential impact encompasses heightened treatment efficacy, reduced side effects, and a shift towards patient-centric care. As nano crystals progress from research to routine clinical use, they have the potential to redefine the landscape of cancer therapy, offering hope for more effective, personalized, and tolerable treatments for individuals facing this challenging disease [44].

6. Conclusion

This state-of-the-art review seeks to provide a comprehensive understanding of the recent strides made in nano crystal science for targeted cancer therapy. By examining the fundamental principles, fabrication techniques, functionalization strategies, and applications, the review aims to contribute to the ongoing discourse on harnessing the potential of nano crystals for advancing precision medicine in the field of oncology.

Abbreviations:

Anti-CCP - Anti-Cyclic Citrullinated Peptide; ESR - Erythrocyte Sedimentation Rate; CRP - C-Reactive Protein; MRI - Magnetic Resonance Imaging; ACR - American College of Rheumatology; MIAN - MTX-Induced Accelerated Nodulosis; COX – Cyclooxygenase; PPIs - Proton Pump Inhibitors; HLA - Human Leukocyte Antigen; MMPs - Matrix Metalloproteinases

Competing Interest and Funding

This study was not funded.

Conflict of Interest

The authors declare that they have no conflict of interest.

Data Availability

No data was used for the research described in the article.

References

[1]. *Smith AM, et al. Targeted Quantum Dot Therapy for Breast Cancer. Nano Lett. 2010;10(11):4134-4139.*

[2]. *Markman JL, et al. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013;65(13-14):1866-1879.*

[3]. *Muthu MS et al. Stimuli-Responsive Targeted Nanocrystals for Drug Delivery to Cancer. Nanomedicine (Lond). 2012 Aug; 7(8): 1261–1273.*

[4]. *Mocan T et al. Quantum dots in imaging and drug delivery. Int J Nanomedicine. 2019; 14: 7177–7194.*

[5]. *Arvizo R et al. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012 May 21;41(7):2943-70.*

[6]. *Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016;1(1):10-29.*

[7]. *Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications. Nano Lett. 2010;10(9):3223-3230.*

[8]. *Davis ME, Chen Z(G), Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-782.*

[9]. *Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131-135.*

[10]. *Van der Meel R, et al. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(10):1007-1017.*

[11]. *Lammers T, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175-187.*

[12]. *Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2-25.*

[13]. *Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.*

[14]. *Dreaden EC, Austin LA, Mackey MA, El-Sayed MA. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv. 2012;3(4):457-478.*
[15]. *Yang H. Nanoparticle-Mediated Brain-Specific Drug Delivery, Imaging, and Diagnosis. Pharm Res. 2010; 27: 1759–1771.*
[16]. *Bhushan B, Khanadeev V, Khlebtsov B, Khlebtsov N, Gopinath P. Impact of albumin based approaches in nanomedicine: Imaging, targeting and drug delivery. Adv Colloid Interface Sci. 2017;249:346-358.*
[17]. *Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003.*
[18]. *Ding H, Wu F. Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics. 2012;2(11):1040-1053.*
[19]. *Zhu S, Song J, Zhang J, et al. Stimuli-Responsive Controlled Drug Release from a Hollow Mesoporous Silica Sphere/Polyelectrolyte Multilayer Core-Shell Structure. Angew Chem Int Ed Engl. 2015;54(32):9195-9199.*
[20]. *Li R, He Y, Zhang S, Qin J, Wang J. Cell membrane camouflaged nanoparticles for drug delivery. J Control Release. 2018;277:158-173.*
[21]. *Wei X, Gao J, Fang RH. Cancer cell membrane-biomimetic nanoparticles for targeted cancer therapy. Nanoscale. 2015;7(41):17611-17626.*
[22]. *Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?. J Control Release. 2016;244(Pt A):108-121.*
[23]. *Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle Technologies for Cancer Therapy. Handb Exp Pharmacol. 2010; (197): 55–86.*
[24]. *Peer D et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2(12): 751–760.*
[25]. *Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941-951.*
[26]. *Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655-672.*
[27]. *Silva GA. Nanotechnology approaches for the regeneration and repair of the central nervous system. Surg Neurol Int. 2011;2:107.*
[28]. *Karimi M et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457-501.*
[29]. *Kostarelos K, Emfietzoglou D, Papakostas A, et al. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer. 2004;112(4):713-721.*
[30]. *Farokhzad OC, Langer R. Impact of Nanotechnology on Drug Delivery. ACS Nano. 2009; 3(1): 16–20.*
[31]. *Tao W, Ji X, Zhu X, Li F, Leong KW, Liu Z. Smart active films: preparation, actuating behavior, and arising stimulus-responsive surfaces. Adv Funct Mater. 2020;30(6):1903847.*
[32]. *Pribul BR et al. Precision Nanomedicine: Regulatory and Scientific Challenges for New Targeted Drug Delivery Systems. NPJ Precis Oncol. 2021; 5(1): 50.*
[33]. *Ventola CL. Progress in Nanomedicine: Approved and Investigational Nanodrugs. P T. 2017;42(12):742-755.*

[34]. *Zhang W, Mumper RJ, Wang C. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond). 2015;10(15):2393-2409.*
[35]. *Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198.*
[36]. *Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138-157.*
[37]. *Akbarzadeh A et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013; 8(1): 102.*
[38]. *Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release. 2014;190:15-28.*
[39]. *Mitragotri S, Anderson DG, Chen X, et al. Accelerating the translation of nanomaterials in biomedicine. ACS Nano. 2015;9(7):6644-6654.*
[40]. *Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016;33(10):2373-2387.*
[41]. *Krol S. Challenges in drug delivery systems for treatment of cancer metastases. Pharmacol Rep. 2018;70(4):759-769.*
[42]. *Wolfram J, Yang Y, Shen J, et al. The nano frontier: A focused review of disease treatment and diagnosis using nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(4):e1552.*
[43]. *Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications. Nano Lett. 2010;10(9):3223-3230.*
[44]. *Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815-823. doi:10.1038/nnano.2011.166.*